Archive for the ‘Droplet Digital PCR’ Category
SelectScience was delighted to announce the QX200™ Droplet Digital™ PCR System, by Bio-Rad, as the winner of the Scientists’ Choice Award for Best New Life Sciences Product of 2013. The award was presented to Bio-Rad at the American Association for Cancer Research (AACR) Annual Meeting 2014.
Click on the photo below to navigate to the SelectScience website and view the video.
Transforming Cancer Research: Droplet Digital™ PCR Plays Integral Role at Fred Hutchinson Cancer Research Center:: Posted by American Biotechnologist on 04-15-2014
It’s no surprise that Droplet Digital PCR (ddPCR) has found its place in the world of cancer research. Bio-Rad’s ddPCR™ technology has a remarkable ability to quantify miniscule amounts of target DNA and RNA, and thus can contribute to early detection of rare tumorigenic mutations against a high background of “normal” DNA as well as to other applications, including identifying cancer subtypes, optimizing drug treatment plans, and studying tumor evolution. At the Fred Hutchinson Cancer Research Center in Seattle, scientists are producing some of the most important advances in prevention, early detection and treatment of cancer and other diseases. They are studying the disease process from every angle seeking to uncover factors that influence a person’s likelihood of getting cancer. Understanding of such factors, of course, can help reduce risk and save lives. To learn more about how Droplet Digital PCR is being wielded to fight against cancer, we caught up with two researchers – Muneesh Tewari and Jason Bielas— who are using Bio-Rad’s QX100™ Droplet Digital™ PCR system in their quest to break through the current limits of nucleic acid detection and quantification.
Since its introduction two years ago, Droplet Digital PCR has transformed multiple fields of research, including infectious disease, cancer biomarker analysis, and genomic variation analysis. In this seminar, Dr. David Dodd describes the application of ddPCR in his research studies with Prof. David Corey and colleagues at UT Southwestern Medical Center at Dallas. The Corey Lab focuses on using antisense oligonucleotides and duplex RNAs to control gene expression in human cancer cells.